This is the authors' abstract. We don't add key points for this paper.
The use of PSAD before MRI lowers overdiagnosis and resource use, while maintaining detection of significant cancer cases. Our results suggest that a PSAD cutoff above 0.075 ng/ml² is not advisable, regardless of age, due to the increased risk of missing cancer cases with Gleason scores ≥3 + 4.
No takes yet. Share an insight, caveat, or question.
Björnebo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: